Alzheimer's Association

Companies, academics, advocates push back on claims they should have disclosed genotype to Alzheimer's trial participants

Three-year Leqembi readout in tau subgroup may be most impressive amyloid mAb data to date

Plus: FDA approves AZ and Sanofi’s RSV prophylactic, and updates from Apellis, J&J, Travere and Acumen

Lilly’s donanemab becomes less effective after tau levels rise

Hearing Wednesday will address Alzheimer’s access, Inflation Reduction Act, other policies GOP says limit access and inhibit innovation

Plus: Bluebird will likely miss submission goal for lovo-cel and updates from Merck, Blueprint, Intarcia, J&J 

Plus: CMS stays the course on Alzheimer's NCD and updates from Blueprint, Apellis, AZ, Nektar, Keymed, Prilenia and more  

β-amyloid therapies in development don’t rely on the presence of Aβ*56, the specific oligomer species in question

BioCentury’s roundup of translational news

Patients unable to access Aduhelm under Medicare could get it under Medicaid, potentially decimating state budgets